I can't understand why holders think JC had such power.
The question lies, if he has been trying to sell Bisantrene for so cheap the last 18 months, then why no takers?
What did previous management have so wrong with RAC/Bisantrene that no pharma wanted in cheaply?
Are those previous issues/concerns still at RAC/with Bisantrene, or have they been rectified?
Hopefully DCB has developed a package that is suitable for BP to pick up... and the new team can deliver.
Ann: Final Director's Interest Notice-Damian Clarke-Bruce, page-23
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
-0.005(0.28%) |
Mkt cap ! $303.3M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.78 | $133.8K | 73.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15072 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 1793 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |